Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Experimental & Molecular Medicine ; : 276-285, 2008.
Article in English | WPRIM | ID: wpr-205429

ABSTRACT

Tropomyosin-related kinase A (TrkA) plays an important role in cell survival, differentiation, and apoptosis in various neuronal and nonneuronal cell types. Here we show that TrkA overexpression by the Tet-On system mimics NGF-mediated activation pathways in the absence of nerve growth factor (NGF) stimulation in U2OS cells. In addition, p53 upregulation upon DNA damage was inhibited by TrkA, and p21 was upregulated by TrkA in a p53-independent manner. TrkA overexpression caused cell death by interrupting cell cycle progression, and TrkA-induced cell death was diminished in the presence of its specific inhibitor GW441756. Interestingly, TrkA-mediated cell death was strongly related to gammaH2AX production and poly (ADP-ribose) polymerase cleavage in the absence of DNA damage inducer. In this study, we also reveal thatgammagammaH2AX production by TrkA is blocked by TrkA kinase inhibitors K-252a and GW441756, and it is also significantly inhibited by JNK inhibitor SP600125. Moreover, reduction of cell viability by TrkA was strongly suppressed by SP600125 treatment, suggesting a critical role of JNK in TrkA-induced cell death. We also found that gammaH2AX and TrkA were colocalized in cytosol in the absence of DNA damage, and the nuclear localization of gammaH2AX induced by DNA damage was partly altered to cytosol by TrkA overexpression. Our results suggest that the abnormal cytosolic accumulation of gammaH2AX is implicated in TrkA-induced cell death in the absence of DNA damage.


Subject(s)
Humans , Anthracenes/pharmacology , Apoptosis/drug effects , Carbazoles/pharmacology , Cell Cycle/drug effects , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Cytosol/drug effects , DNA Damage/drug effects , Doxorubicin/pharmacology , Histones/metabolism , Indole Alkaloids/pharmacology , MAP Kinase Kinase 4/antagonists & inhibitors , Nerve Growth Factor/antagonists & inhibitors , Phosphorylation/drug effects , Protein Binding , Protein Transport/drug effects , Receptor, trkA/antagonists & inhibitors , Signal Transduction , Transfection
2.
Experimental & Molecular Medicine ; : 408-416, 2006.
Article in English | WPRIM | ID: wpr-53149

ABSTRACT

c-Jun N-terminal kinase (JNK) is activated during hepatic reperfusion, and JNK inhibitors are known to protect other major organs from ischemia-reperfusion (I/R) injury. We attempted to determine the effect of SP600125, a JNK inhibitor, on hepatic I/R injury using a partial ischemia model in mice. Compared to a vehicle-treated group, the SP600125-treated group showed a greater increase in serum ALT levels 24 h after reperfusion with more severe parenchymal destruction and leukocyte infiltration. Similarly, tissue myeloperoxidase and malondialdehyde levels were higher in the SP600125-treated group, and chemokine expression was also higher in the SP600125-treated group. These data, which are contradictory to previous results, indicate that JNK inhibition by SP600125 may be harmful in hepatic I/R injury. Therefore, care must be taken when investigating the therapeutic use of JNK inhibitors in hepatic I/R injury, especially in the context of the effects of JNK inhibition on inflammatory infiltration.


Subject(s)
Mice , Male , Animals , Reperfusion Injury/drug therapy , Oxidative Stress/drug effects , Mice, Inbred C57BL , Matrix Metalloproteinase 9/metabolism , MAP Kinase Kinase 4/antagonists & inhibitors , Liver/cytology , Chemokines/metabolism , Anthracenes/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL